After finishing at $45.16 in the prior trading day, Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) closed at $46.15, up 2.19%. In other words, the price has increased by $+0.99 from its previous closing price. On the day, 555385 shares were traded.
Ratios:
Our goal is to gain a better understanding of RYTM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.43 and its Current Ratio is at 5.58. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on December 19, 2023, Upgraded its rating to Overweight and sets its target price to $55 from $29 previously.
On August 01, 2023, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $22 to $27.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 14 when Shulman Joseph sold 1,089 shares for $50.01 per share. The transaction valued at 54,461 led to the insider holds 30 shares of the business.
Shulman Joseph sold 1,865 shares of RYTM for $93,250 on Feb 13. The Chief Technical Officer now owns 1,119 shares after completing the transaction at $50.00 per share. On Feb 13, another insider, Mazabraud Yann, who serves as the EVP, Head of International of the company, sold 957 shares for $49.84 each. As a result, the insider received 47,697 and left with 6,745 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RYTM now has a Market Capitalization of 2.74B and an Enterprise Value of 2.47B. For the stock, the TTM Price-to-Sale (P/S) ratio is 35.22 while its Price-to-Book (P/B) ratio in mrq is 16.16. Its current Enterprise Value per Revenue stands at 31.87 whereas that against EBITDA is -14.50.
Stock Price History:
Over the past 52 weeks, RYTM has reached a high of $52.57, while it has fallen to a 52-week low of $15.50. The 50-Day Moving Average of the stock is 45.24, while the 200-Day Moving Average is calculated to be 28.55.
Shares Statistics:
The stock has traded on average 758.77K shares per day over the past 3-months and 670.73k shares per day over the last 10 days, according to various share statistics. A total of 59.43M shares are outstanding, with a floating share count of 52.06M. Insiders hold about 11.90% of the company’s shares, while institutions hold 105.85% stake in the company. Shares short for RYTM as of Jan 31, 2024 were 8.86M with a Short Ratio of 11.68, compared to 8.14M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 15.00% and a Short% of Float of 24.34%.
Earnings Estimates
Its stock is currently analyzed by 7 different market analysts. On average, analysts expect EPS of -$2.09 for the current quarter, with a high estimate of -$0.64 and a low estimate of -$2.4, while EPS last year was -$0.92. The consensus estimate for the next quarter is -$0.64, with high estimates of -$0.52 and low estimates of -$0.76.
Analysts are recommending an EPS of between -$1.73 and -$4.76 for the fiscal current year, implying an average EPS of -$3.45. EPS for the following year is -$1.68, with 8 analysts recommending between $0.52 and -$2.57.
Revenue Estimates
7 analysts predict $27.66M in revenue for the current quarter. It ranges from a high estimate of $31.5M to a low estimate of $25.8M. As of the current estimate, Rhythm Pharmaceuticals Inc.’s year-ago sales were $11.47M, an estimated increase of 141.20% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $31.95M, an increase of 66.20% less than the figure of $141.20% in the same quarter last year. There is a high estimate of $34.5M for the next quarter, whereas the lowest estimate is $29.6M.
A total of 9 analysts have provided revenue estimates for RYTM’s current fiscal year. The highest revenue estimate was $155.3M, while the lowest revenue estimate was $115.61M, resulting in an average revenue estimate of $135.64M. In the same quarter a year ago, actual revenue was $77.43M, up 75.20% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $196.17M in the next fiscal year. The high estimate is $225M and the low estimate is $164.72M. The average revenue growth estimate for next year is up 44.60% from the average revenue estimate for this year.
